ABINGWORTH LLP
Q3 2018 Form 13-F
CIK 0001397144
· Institutional investment manager
Holdings reported by
Carlyle Group Inc since Q1 2023
$168.2M Reported Value Total
Reported value
$168.2M
Quarter over quarter
-3.7%
Holdings
16
Top-10 concentration
93.5%
Filing Structure
Reports holdings for
- Carlyle Group Inc · File #028-15025 · Q3 2022 – Q4 2022 · declared by one filing
- Abingworth Management LTD (not a 13F filer in our records) · Q2 2013 – Q2 2015 · declared by one filing
Holdings reported by
- Carlyle Group Inc · since Q1 2023
Key People
Named on the latest Form 13-F filing — not necessarily an owner
John Heard
General Counsel
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2018 13F record
Q3 2018 13F filing summary
| Period of report | September 30, 2018 |
|---|---|
| Filed | November 14, 2018 |
| Form | 13F-HR |
| Reported value | $168.2M |
| Positions | 16 |
| Change in reported value | -3.9% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 11.8% |
| Top-10 concentration | 93.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2022 13F
Filed Feb 10, 2023
|
19 | $306.9M |
|
Q3 2022 13F
Filed Nov 10, 2022
|
19 | $292.5M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
21 | $312.4M |
|
Q1 2022 13F
Filed May 16, 2022
|
20 | $352.5M |
|
Q4 2021 13F
Filed Feb 16, 2022
|
20 | $412.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
20 | $440.7M |
|
Q2 2021 13F
Filed Aug 16, 2021
|
19 | $323.5M |
|
Q1 2021 13F
Filed May 17, 2021
|
17 | $289.6M |
|
Q4 2020 13F
Filed Mar 1, 2021
|
15 | $292.3M |
|
Q3 2020 13F
Filed Nov 16, 2020
|
17 | $467.5M |
|
Q2 2020 13F
Filed Aug 14, 2020
|
16 | $357.7M |
|
Q1 2020 13F
Filed May 14, 2020
|
16 | $150.6M |
|
Q4 2019 13F
Filed Feb 14, 2020
|
16 | $206.9M |
|
Q3 2019 13F
Filed Nov 14, 2019
|
14 | $158.2M |
|
Q2 2019 13F
Filed Aug 14, 2019
|
14 | $260.8M |
|
Q1 2019 13F
Filed May 15, 2019
|
14 | $111.7M |
|
Q4 2018 13F
Filed Feb 14, 2019
|
16 | $110.1M |
|
Q3 2018 13F
Filed Nov 14, 2018
|
16 | $168.2M |
|
Q2 2018 13F
Filed Aug 14, 2018
|
16 | $175.0M |
|
Q1 2018 13F
Filed May 15, 2018
|
16 | $160.9M |
19 earlier quarters on file — choose one from the quarter menu above.
Top 16 holdings · Q3 2018
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CRSP Crispr | $54.9M | 32.61% |
| 2 | SIEN Sientra | $52.5M | 31.22% |
| 3 | VRNA Verona | $11.3M | 6.7% |
| 4 | PRTK Paratek | $10.0M | 5.97% |
| 5 | OBSVF Obseva | $7.9M | 4.72% |
| 6 | CHMA Chiasma | $7.5M | 4.45% |
| 7 | TARA Proteon | $3.8M | 2.28% |
| 8 | ADAPY Adaptimmune | $3.4M | 2.02% |
| 9 | CBAY Cymabay | $3.0M | 1.8% |
| 10 | RARE Ultragenyx | $2.9M | 1.73% |
| 11 | CLLS Cellectis | $2.8M | 1.68% |
| 12 | AUPH Aurinia Pharma | $2.7M | 1.58% |
| 13 | SRRA Sierra Oncology | $2.5M | 1.46% |
| 14 | AVEO Aveo Pharma | $1.3M | 0.78% |
| 15 | IMDZ Immune Design | $1.2M | 0.71% |
| 16 | HSGX Histogenix | $473.0K | 0.28% |
Values as reported on the Q3 2018 Form 13F. Every position is in the holdings table below.